Supply Life-Changing Therapies from Clinic to Commercialization, Through Effective Scale Up, CoGs Management & Digital Solutions to Improve the Patient Experience
In 2025, cell and gene therapy reached a pivotal moment. Amid rising tariffs, shifting regulations, and capacity constraints, the industry gained clarity on what it takes to scale successfully. As a result, the focus on scaling novel therapies safely and efficiently has never been stronger, introducing a new era of operational excellence and expanded patient access.
As we enter 2026, expanding into challenging global markets while navigating geopolitical uncertainty has never been more critical. Success will depend on stronger standardization, cross-functional collaboration, and consistent worldwide distribution. This year’s summit provides essential frameworks for success, including strategies for LATAM, Australia, and parts of Africa, practical guidance for securing dependable global shipping routes, and proven approaches to improving coordination across the supply chain.
Designed by and for supply chain leaders across biopharma, including Roche, Bristol Myers Squibb, Johnson & Johnson, Genentech, ProKidney, and Vyriad the 7th Supply Chain & Logistics for Cell & Gene Therapy Summit delivers best-in-class perspectives on global patient supply, cost of goods optimization, and accelerating clinical and commercial programs through digital innovation. With strong end-to-end focus, the agenda reflects the real challenges facing advanced therapy supply chains today.
If you are a supply chain leader in cell and gene therapy, this is your must-attend opportunity to connect with peers, benchmark best practices, and gain actionable insights to build a resilient, future-ready supply chain that delivers therapies to patients, reliably and at scale.
Attending Companies Include